AbbVie Pressures Biohaven in Migraine Prevention with FDA Approval for its CGRP Blockbuster-to-be Qulipta
From: FiercePharma By: Angus Liu Tuesday, AbbVie said the FDA has green-lighted its Qulipta, or atogepant, for prevention of episodic migraine. The go-ahead follows the landmark approval of Biohaven’s Nurtec ODT as the first oral anti-CGRP drug for preventing migraine, setting up a direct battle between two meds that both bear big sales expectations. Doctors’ initial […]
Unmet Need for New Treatment Options and Barriers to Adalimumab Use in Hidradenitis Suppurativa
Author: Gianna Melendez INTRODUCTION: Hidradenitis suppurativa (HS), or acne inversa, is a chronic inflammatory condition that presents as painful and recurrent abscesses that progress to sinus tracts and scarring in the intertriginous locations of the body, causing low quality of life in most patients. HS often develops when hair follicles become blocked and is […]
Uptake of Baricitinib For The Treatment of Moderate-To-Severe Atopic Dermatitis in Germany
Author: Gianna Melendez INTRODUCTION: Since 2017, dupilumab has been the only advanced systemic option for patients with moderate-to-severe atopic dermatitis (AD), leaving a large unmet need for new treatments. Though widely perceived as efficacious and safe, most EU5 dermatologists agree that the biologic does not work well in all moderate-to-severe AD patients. In October […]
Biohaven’s Nurtec ODT Garners Greater Early-Line Use as a Preventive Therapy Among Patients with Less Severe Migraine Compared to Eli Lilly’s Emgality, According to Spherix Patient-Level Data
While efficacy expectations play a key role in the decision to prescribe Nurtec ODT as a preventive therapy, the gepant’s convenient oral dosing profile drives wins over competitors like Emgality EXTON, Pa., September 23, 2021/PRNewswire/ – Just weeks after the FDA approval of Nurtec ODT’s label expansion for the preventive treatment of episodic migraine, Eli […]
Two-Thirds of Neurologists Expect to Start Some Patients on Aduhelm Next Year: Survey
From: McKnights Long Term Care News By: Alicia Lasek The outlook for the use of the drug is looking up, according to surveyor Spherix Global Insights. There are small increases in the number of Aduhelm prescribers and an uptick in patients for whom the therapy has been initiated. This is compared with flat activity seen in […]
Biogen’s Alzheimer’s Drug Aduhelm Slowly Gaining Steam Among Prescribing Neurologists, Study Finds
From: FiercePharma By: Noah Higgins-Dunn A week ago, Biogen CEO Michel Vounatsos sent the company’s shares into a nosedive after disclosing its launch of Alzheimer’s disease med Aduhelm was slower than expected. But according to one new analysis, there may be signs things are looking up. Data collected from a survey of 74 neurologists collected […]
Aduhelm Launch Trends Show Some Early Signs of Progress as the Biogen Team Aims to Moderate Near-Term Expectations
New research from Spherix’s Launch Dynamix™ service captures neurologists’ current perceptions and reported prescribing behavior for the first-to-market disease-modifying therapy for the treatment of Alzheimer’s disease EXTON, Pa., September 16, 2021/PRNewswire/ — The June 2021 approval of Biogen/Eisai’s Aduhelm fueled high initial expectations for the first-to-market disease-modifying therapy (DMT) for the treatment of Alzheimer’s disease. […]
Biohaven’s Ambitious Nurtec ODT Marketing Strategy Pays Dividends With Doctors in Migraine Market: Analyst
From: FiercePharma By: Beth Snyder Bulik Biohaven went all-in on marketing its added preventative indication for oral migraine med Nurtec. And now it’s reaping the rewards with doctors. Three months post-approval, 96% of neurologists were aware of the brand, while 65% are “highly familiar” with it, according to Spherix Global Insights’ postlaunch report…(read more)
Following the Recent Label Expansion, Biohaven’s Nurtec ODT Has Come Out Strong in the Migraine Prevention Market
Spherix Global Insights data show Nurtec ODT expanding its dominance of the CGRP class for migraine prevention with little anticipated share erosion for its closest competitors – Amgen’s Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality EXTON, Pa., September 9, 2021 /PRNewswire/ — In May 2021, the FDA approved the label expansion of Biohaven’s Nurtec ODT for the […]
Woodcock Calls for HHS OIG Investigation Into Aduhelm Approval
From: Policy & Medicine By: Thomas Sullivan As reported by Fierce Pharma, physicians are losing trust in the FDA due to the agency’s recent controversial approvals. Physicians’ trust in the agency is plummeting, according to a recent survey by Spherix Global Insights. More than 40% of the doctors surveyed said their confidence in the FDA has dropped over the […]
